Adventrx Pharmaceuticals Cancer Company Intelligence Report

Pharma Business Daily
Claim your FREE trial subscription!

Cancer:

Adventrx Pharmaceuticals Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing September 2005

Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. On 10th October 2000, Biokeys Pharmaceuticals was formed as the result of a merger of equals between BioQuest
Inc, which was a public company, and Biokeys Inc, which was a privately-held entity. In May 2002, Biokeys
Pharmaceuticals became a fully reporting company and in June 2002 the company's common shares were accepted
for quotation on the NASD Over the Counter Bulletin Board. Effective 13th June 2003, Biokeys changed its name to
ADVENTRX Pharmaceuticals. According to the company, it believes this new name better reflects the strength of its
technology platforms.
In July 2004, ADVENTRX relocated to a new facility in the Sorrento Mesa area of San Diego which is able to
accommodate new staff and will allow the company to increase the scope and progress of its clinical and product
development programmes.

Number of pages - 8

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.